Friday, September 20, 2013

UK dry eye market... someone's noticing us....

I was reminded today of a comic one of my siblings reproduced artistically for one of our parents on their birthday when I was little. I don't remember the picture but the caption read, "If you feel like no one cares you're alive, try missing a few car payments."

Well, UK dry eye patients, if you feel like no one cares about you, (grin) at least the stock pickers do. If your doctor doesn't seem to, find another doctor... thankfully more and more doctors who give a fig for dry eye really are emerging.

By Reportlinker
Published: Tuesday, Sep. 17, 2013 - 7:55 am
NEW YORK, Sept. 17, 2013 -- /PRNewswire/ -- announces that a new market research report is available in its catalogue:

GlobalData has released its new Country report, "PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022". Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.
The DES market in the UK is projected to grow substantially during the forecast period. During the forecast period, the primary growth driver of the DES market in the UK will be the launch of the EU's first prescription product for DES, as well as the rapidly increasing population of DES patients.
Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the UK from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the UK DES market.

No comments: